Our Mission

We discovered the physics layer of biology.

InfiniGraph was founded on a discovery that changes the economics of drug development — every protein carries a physical signature that governs how it responds to drugs, and no existing tool could calculate it. We built HARMONY to change that.

What We Do

Safer drugs, from physics.

HARMONY recovers drugs that failed safety review and screens pipeline compounds before they fail. InfiniGraph built the physics behind it.

Physics at the Core

HARMONY is built on the laws of physics, so its results are reproducible, traceable, and defensible in front of any scientific or regulatory audience.

Speed That Matters

In drug development, every month of delay is a month patients wait. HARMONY compresses the earliest and most critical stage of drug development from years to hours.

A Platform for Partners

HARMONY is not a bet on one drug. It is infrastructure that can run across any target, any disease, any indication. We are actively seeking pharma and biotech partners who see the same opportunity we do.

Leadership

Physics, medicine, and execution.

InfiniGraph is led by a founding team that has built category-defining companies, published in Nature, and invented the physics that makes HARMONY possible. Meet the full team →

Chase K. McMichael

Founder · CEO · Chief Science Officer

Founder, CEO, and Chief Science Officer. Developed the ARC-X platform and THE ONE equation, a discovery that transforms molecular detection and opens new frontiers in chemistry and quantum-inspired physics. Created HARMONY as the culmination of these breakthroughs. Inventor or co-inventor of 13 U.S. patents with numerous technical publications.

Lincoln D. Nadauld, MD, PhD

Chief Medical Officer

Practicing precision oncologist at Intermountain Health. First and senior author in Nature Genetics and Nature. Leads clinical development strategy and ClinVar-based target selection.

Michael Wiley, JD

General Counsel

Co-founder of Guardant Health (NASDAQ: GH, $3B+ market cap). Deep expertise in life science IP strategy, licensing, and commercialization. Oversees InfiniGraph's IP fortress and pharma partnership structure.